Although molecular biology studies indicate the presence of adenosine A 2A receptors in the rat hippocampus, the pharmacological characterization of adenosine A 2A receptor binding and of its putative facilitatory effects has revealed features essentially different from these found for adenosine A 2A receptors in most preparations. We now confirmed that activation of adenosine 
Introduction
Adenosine can either decrease or facilitate the evoked release of neurotransmitters in the nervous system by activating inhibitory adenosine A 1 or facilitatory adenosine A 2A receptors, respectively (Cunha, 2001) . As occurs for the modulation of glutamate (Ambrósio et al., 1997; Lopes et al., 2002) and serotonin release (Okada et al., 2001) , the modulation of acetylcholine release by adenosine in the hippocampus is also controlled by both adenosine A 1 and A 2A receptors (Cunha et al., 1994a; Jin and Fredholm, 1997) . The presence of adenosine A 2A receptors in the hippocampus has been confirmed using molecular biology studies, like polymerase chain reaction (PCR), in situ hybridization (Cunha et al., 1994b) and Northern blot analysis (Peterfreund et al., 1996) , but binding studies have revealed an atypical binding pattern (Cunha et al., 1996) and G protein coupling (Cunha et al., 1999) of these putative adenosine A 2A receptors. Some functional peculiarities of the facilitatory effects of the prototypical adenosine A 2A receptor agonist, CGS 21680 (Fredholm et al., 1994) , include the strict dependency on co-activation of adenosine A 1 receptors in the control of glutamate release (Lopes et al., 2002) , the atypical pharmacology in the control of GABA release (Cunha and Ribeiro, 2000a) and the coupling to protein kinase C in the control of excitatory synaptic transmission (Cunha and Ribeiro, 2000b; Lopes et al., 2002) . Thus, none of the neurotransmitter systems controlled by putative adenosine A 2A receptors has yet proven to obey to a clear and typical adenosine A 2A receptor pharmacology and to be coupled to the postulated cAMP/protein kinase A transducing pathway (Fredholm et al., 1994) .
We now report that the control by adenosine A 2A receptors of acetylcholine release from hippocampal nerve terminals obeys to the expected pharmacology for adenosine A 2A receptors (antagonism by ZM 241385 and SCH 58261 but not by DPCPX) and requires the activation of the adenylate cyclase/cAMP/protein kinase A pathway rather than the protein kinase C transducing pathway.
Materials and methods

Drugs and solutions
8-Bromoadenosine-3V:5V-cyclic monophosphate (8-bromo-cAMP), hemicholinium-3, 7ß-deacetyl-7ß-(g-Nmethylpiperazino)butyrylforskolin (forskolin), veratridine and 1,9-dideoxyforskolin were from Sigma; 2-[4-(2-p-carboxyethyl)phenylamino]-5V-N-ethylcarboxamidoadenosine (CGS 21680), phorbol-12,13-didecanoate and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) were from RBI; H-89 and bisindolylmaleimide were from Calbiochem; 4-(2-[7-amino-2-{2-furyl}{1,2,4}triazolo{2,3a}{1,3,5}triazin-5-yl-amino]ethyl)phenol (ZM 241385) was from Tocris; and [methyl-
3 H]choline (specific activity 41.3 Ci/mmol) was from Amersham. Rolipram [4-(3V-cyclopentyloxy-4V-methoxyphenyl)-2-pyrrolidone (4-RS)] was a gift of Schering; 5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4 triazolo[1,5-c]pyrimidine (SCH 58261) was provided by E. Ongini (Schering Plough, Milan); 2-hexynyl-5V-N-ethylcarboxamidoadenosine (HENECA) was offered by G. Cristalli (Univ. Camerino, Italy); and goat purified IgG anti-adenosine A 2A receptor antibody (200 Ag/ml) was from Santa Cruz Biotechnology-Europe. All other reagents were of the highest purity available.
Forskolin was made up to a 20 mM stock solution in ethanol. Dideoxyforskolin was made up to a 20 mM and rolipram in a 50 mM stock solution in dimethylsulfoxide. CGS 21680, HENECA, ZM 241385, SCH 58261, phorbol-12,13-didecanoate, H-89 and bisindolylmaleimide were made up into 5 mM stocks in dimethylsulfoxide. DPCPX was made up into a 5 mM stock in 99% dimethylsulfoxide-1% NaOH (1 M) (v/v). Aqueous dilution of these stock solutions was made daily.
[ 3 H]acetylcholine release from nerve terminals
The release of [ 3 H]acetylcholine from a synaptosomal fraction from the rat hippocampus was carried out as previously described (Cunha et al., 1995) using male Wistar rats (130 -140 g) decapitated after anesthesia under halothane atmosphere, following the European Union guidelines for handling experimental animals. Briefly, the synaptosomes were equilibrated for 10 min at 37 jC, loaded with [ 3 H]choline (10 ACi/ml, 0.125 AM), layered over Whatman GF/C filters into 90-Al chambers and superfused at a flow rate of 0.6 ml/min with a gassed (95% O 2 and 5% CO 2 ) Krebs solution of the following composition: NaCl 125 mM, KCl 3 mM, NaH 2 PO 4 1 mM, NaHCO 3 25 mM, CaCl 2 1.5 mM, MgSO 4 1.2 mM, glucose 10 mM and hemicholinium-3 0.01 mM (see Cunha et al., 1995) . After a 30-min washout period, the synaptosomes were stimulated with veratridine (10 AM) for 2 min, at 6 and 26 min after starting sample collection (S 1 and S 2 ). At the end of the experiments, the filters were removed from the chambers to determine the amount of tritium retained by the synaptosomes. At least 12 h after addition of 5 ml of scintillation cocktail (Scintran T, BDH) to each of the 2-min effluent samples and to the filters, scintillation counting was performed with a 55-60% efficiency during 2 min. The fractional release of tritium was expressed in terms of percentage of total radioactivity present in the tissue at the time of sample collection. The release of tritium evoked by each veratridine pulse, i.e. the evoked release, was calculated by integration of the area of the peak upon subtraction of the estimated basal tritium outflow from the total outflow of tritium due to stimulation. To measure [
3 H]actylcholine in the total tritium outflow, [ 3 H]acetylcholine was separated using a cation exchanger, tetraphenylboron, after phosphorylation of [ 3 H]choline, as previously described (Cunha et al., 1994a) .
When the effect of drugs on the release of acetylcholine was investigated, these drugs were added to the superfusion medium 6 min before S 2 , i.e. 20 min after starting sample collection, and remained in the bath up to the end of the experiment. The effect of these drugs on the evoked release of acetylcholine was expressed by alterations of the ratio between the evoked release due to second stimulation period and the evoked release due to the first stimulation period (S 2 /S 1 ratio). This ratio is remarkably constant in between experiments, in contrast to absolute values of S 1 that vary in between experiments, precluding a reliable analysis of this parameter. When we evaluated the modifications of the effect of these drugs by modifiers, the modifiers were applied 15 min before starting sample collection and hence were present during S 1 and S 2 . When present during S 1 and S 2 , none of the modifiers (ZM 241385, SCH 58261, DPCPX, 8-Br-cAMP, forskolin, dideoxyforskolin, rolipram, H-89, bisindolylmaleimide or phorbol-12,13-didecanoate) , significantly altered ( P >0.05) the S 2 /S 1 as compared to the S 2 /S 1 ratio obtained in the absence of the modifiers (data not shown).
The values are presented as mean F S.E.M. The percentage effect of drugs was calculated in each individual experiment and the S.E.M. is relative to the variance of this percentage effect. To test the significance of the effect of drugs versus control, a paired Student's t test was used. When making comparisons from a different set of experiments with control, a one-way analysis of variance (ANOVA) was used, followed by Dunnett's test. P < 0.05 was considered to represent a significant difference.
Western blot analysis of A 2A receptors
The analysis of adenosine A 2A receptor immunoreactivity was carried out in whole membranes of the striatum and in membranes from a Percoll-purified synaptosomal fraction of the hippocampus, prepared as previously described (e.g. Cunha et al., 1996) . After determining the amount of protein (Spector, 1978) , each sample was diluted with two volumes of a solution containing 8 M urea, 100 mM dithiothreitol, 2% (w/v) sodium dodecyl sulfate and 375 mM Tris -HCl pH 6.8 and incubated for 2 h at 37 jC. These diluted samples and the pre-stained molecular weight markers (Amersham) were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (10% with a 4% concentrating gel) under reducing conditions (Laemmeli, 1970) and electro-transferred to polyvinylidene difluoride membranes (0.45 Am from Amersham). After blocking for 2 h at room temperature with 5% milk in Tris-buffered saline, pH 7.6 containing 0.1% Tween 20 (TBS-T), the membranes were incubated overnight at 4 jC with the anti-adenosine A 2A receptor antibody (1:100 dilution). After four washing periods for 10 min with TBS-T containing 0.5% milk, the membranes were incubated with the alkaline phosphataseconjugated anti-goat secondary antibody (1:2000 dilution from Calbiochem) in TBS-T containing 1% milk during 90 min at room temperature. After five 10-min washes in TBS-T 0.5% milk, the membranes were incubated with Enhanced Chemi-Fluorescent during 5 min and then analysed with a Storm (Molecular Devices).
Results
Pharmacological characterization of facilitatory adenosine A 2A receptors in hippocampal cholinergic nerve terminals
The two selective adenosine A 2A receptor agonists, CGS 21680 and HENECA (1-100 nM) (Fredholm et al., 1994) , facilitated the evoked release of acetylcholine from hippocampal nerve terminals (Fig. 1A) , as previously described (Cunha et al., 1995 (Cunha et al., , 1997 . The concentration-dependent curve for the facilitation of the evoked release of acetylcholine was similar for the two agonists, with increasing effects with increasing applied concentrations of the agonist, CGS 21680 being slightly more potent than HENECA (Fig. 1A) . Also, for both agonists, there was a decreased facilitation of the evoked release of acetylcholine at the highest concentrations of the agonists tested that may either result from an adenosine A 2A receptor-induced desensitization (see Cunha, 2001 for discussion) or from a loss of selectivity towards inhibitory adenosine A 1 receptors (see, e.g. Lupica et al., 1990) .
Previous studies by our group had already tentatively characterized this facilitatory effect of acetylcholine release by CGS 21680 and HENECA as being mediated by adenosine A 2A receptors based on the efficiency of the adenosine A 2A receptor antagonists, CSC (8-(3-chlorostyryl)caffeine) and of ZM 241385, to prevent these effects (Cunha et al., 1995 (Cunha et al., , 1997 . However, some studies have cast doubts on the real selectivity of CSC and of ZM 241385 (Cunha et al., 1996; de Mendonc ßa and Ribeiro, 1994; Lindström et al., 1996; Lopes et al., 1999a) towards adenosine A 1 receptormediated responses. Thus, we decided to test the ability of SCH 58261 to antagonize the CGS 21680-and HENECAinduced facilitation of acetylcholine release, since this compound has repeatedly been shown to behave as a selective antagonist of adenosine A 2A receptors (Cunha et al., 1999; Fredholm et al., 1998; Lindström et al., 1996) . As illustrated in Fig. 1B , the facilitatory effects of either CGS 21680 (30 nM) or HENECA (30 nM) were nearly abolished in the presence of SCH 58261 (20 nM) and were virtually , 1997) , and was assumed to represent exocytotic ACh release. HENECA or CGS21680 were added 7 min before S 2 and remained in the bath up to the end of the experiment. The facilitatory effects of HENECA or CGS21680 were calculated from the alteration of the S 2 /S 1 ratio compared with the S 2 /S 1 ratio in the absence of these adenosine A 2A receptor agonists. *P < 0.05 compared with 0%. In (B), the drugs were present either during S2 (added 7 min before S2) or in S1 and S2 (added 15 min before starting sample collection) as indicated by the symbols below each column. SCH 58261 (20 nM) or DPCPX (20 nM) when present during S 1 and S 2 did not modify the S 2 /S 1 ratio compared with control. *P < 0.05 compared with the effect of CGS 21680 (30 nM, first bar from the left), **P < 0.05 compared with the effect of HENECA (30 nM, forth column from the left). The results are mean F S.E.M. of three to four experiments in (A) and (B).
unaffected by the adenosine A 1 receptor antagonist, DPCPX (20 nM).
So far, we have only been able to show that activation of adenosine A 2A receptors with selective adenosine A 2A receptor agonists triggered a facilitation of acetylcholine release with a pharmacology compatible with the activation of adenosine A 2A receptors. We then sought to demonstrate that a facilitatory response could be obtained with nonselective adenosine receptor ligands. It is difficult to use adenosine itself to carry out a pharmacological characterization of adenosine receptor-mediated effects since adenosine is rapidly taken up and metabolized by virtually all eukaryotic cell types. Thus, we tested the effect of the closest chemical analogue of adenosine, 2-chloroadenosine, which is less prone to uptake and metabolism and activates all adenosine receptor subtypes (Fredholm et al., 1994) . As illustrated in Fig. 2A , 2-chloroadenosine (10 AM) inhibited the evoked release of acetylcholine, in accordance with previous observations in hippocampal slices (Cunha et al., 1994a) . This inhibitory effect was abolished by the adenosine A 1 receptor selective antagonist, DPCPX (20 nM), indicating that it is an adenosine A 1 receptor-mediated effect. In the presence of DPCPX (20 nM), we now observed that 2-chloroadenosine facilitated the evoked release of acetylcholine (Fig. 2B ). This facilitatory effect was prevented by SCH 58261 (20 nM), indicating that it is mediated by facilitatory adenosine A 2A receptors (Fig. 2C) . These results show that the evoked release of acetylcholine is under the control of both inhibitory A 1 and facilitatory A 2A receptors, and that the exogenous addition of a nonselective adenosine receptor agonist mainly leads to the activation of inhibitory adenosine A 1 rather than of facilitatory adenosine A 2A receptors.
Transducing system operated by facilitatory adenosine A 2A receptors in hippocampal cholinergic nerve terminals
Classically, adenosine A 2A receptors are recognized as being coupled to the adenylate cyclase/cAMP transducing pathway (Fredholm et al., 1994) . However, several evidences indicate that some facilitatory effects triggered by the prototypical adenosine A 2A receptor agonist, CGS 21680, in low nanomolar concentrations, are dependent on protein kinase C activation (Cunha and Ribeiro, 2000a,b; Lopes et al., 2002) . We first tested the effect of the direct activation of protein kinase A and of protein kinase C on acetylcholine release. The direct activation of protein kinase C with its direct cell-permeable activator phorbol-12,13-didecanoate (250 nM) facilitated the evoked release of acetylcholine by 13.1 F 2.2% (n = 4). As illustrated in Fig. 3 , the protein kinase C inhibitor, bisindolylmaleimide (1 AM), significantly attenuated this facilitatory effect of phorbol-12,13-didecanoate, indicating that it was indeed due to protein kinase C activation (n = 4). The direct activation of protein kinase A with its direct cell-permeable activator 8-bromocyclic AMP (8-Br-cAMP, 0.5 mM) facilitated the evoked release of acetylcholine by 21.2 F 3.4% (n = 4). As illustrated in Fig. 3 , the protein kinase A inhibitor, H-89 (1 AM), completely prevented this facilitatory effect of 8-Br-cAMP, indicating that it was indeed due to protein kinase A activation (n = 4). In accordance with previous suggestions that high micromolar concentrations of 8-Br-cAMP might trigger the activation of inhibitory A 1 receptors (e.g. Dunwiddie and Hoffer, 1980; Brundege et al., 1997) , it was observed that 8-Br-cAMP (0.5 mM) in the presence of H-89 (1 AM) now inhibited the evoked release of acetylcholine (Fig. 3) .
We then tested if the activation or inhibition of the protein kinase A and protein kinase C pathways impacted on the ability of adenosine A 2A receptors to facilitate the evoked release of acetylcholine (Fig. 4) . The activation of protein kinase A with 8-Br-cAMP (0.5 mM, n = 4) or with forskolin (10 AM, n = 4), but not with the inactive analogue 1,9-dideoxyforskolin (10 AM, n = 2), blunted the ability of CGS 21680 (30 nM) to facilitate the evoked release of acetylcholine (Fig. 4A) . Likewise, inhibition of protein kinase A activity with H-89 (1 AM, n = 4) also attenuated the ability of CGS 21680 (30 nM) to facilitate the evoked release of acetylcholine (Fig. 4A) . To further re-enforce our conclusion that adenosine A 2A receptor facilitation of acetylcholine release depends on the activation of the cAMP/protein kinase A pathway, we tested if the inhibition of the phosphodiesterases responsible for the catabolism of cAMP would enhance the effect of a sub-maximal concentration of CGS 21680. CGS 21680 (1 nM) facilitated the evoked release of acetylcholine by 4.4 F 1.1% (n = 3), but in the presence of the phosphodiesterase IV , and the ability of the protein kinase C activator, phorbol-12,13-didecanoate (250 nM), to facilitate [ 3 H]ACh release, an effect attenuated by the protein kinase C inhibitor, bisindolylmaleimide (1 AM). The drugs were present either during S2 (added 7 min before S2) or in S1 and S2 (added 15 min before starting sample collection) as indicated by the symbols below each column. H-89 (1 AM) or bisindolylmaleimide (1 AM) when present during S 1 and S 2 did not modify the S 2 /S 1 ratio compared with control. *P < 0.05 compared with 0%; **P < 0.05. The results are mean F S.E.M. of four experiments.
inhibitor, rolipram (30 AM, n = 4), CGS 21680 (1 nM) now facilitated the evoked release of ACh by 11.2 F 2.6% (Fig.  4B) . Finally, the observation that the protein kinase C inhibitor, bisindolylmaleimide (1 AM, n = 4), failed to significantly ( P < 0.05) modify the ability of CGS 21680 (30 nM) to facilitate the evoked release of acetylcholine strongly suggests that the adenosine A 2A receptor-mediated facilitation of acetylcholine release might not depend on protein kinase C activation (Fig. 4C ).
Immunological identification of adenosine A 2A receptors in hippocampal nerve terminals
The pharmacological characterisation of adenosine A 2A receptors has been mostly carried out in the striatum (Fredholm et al., 1994) . To further re-enforce that hippocampal nerve terminals are indeed endowed with a molecular entity identical to striatal adenosine A 2A receptors, we investigated by Western blot analysis if the molecular entities recognized by adenosine A 2A receptor antibodies displayed a similar electrophoretic mobility in hippocampal and striatal membranes. In Fig. 5 is shown a Western blot, representative of four similar blots carried out in membranes from different animals, demonstrating the presence in hippocampal nerve terminal membranes of a band of similar apparent molecular weight (42 kDa) to that recognized in the striatum by adenosine A 2A receptor antibodies, albeit with a much lower intensity. Control experiments showed that the lack of addition of the primary antibody resulted in background fluorescence in the gel (data not shown).
Discussion
The present study presents evidences for the presence of adenosine A 2A receptors with pharmacological and biochemical features identical to these found for the prototypical adenosine A 2A receptors in the striatum. In fact, we identified by Western blot an adenosine A 2A receptor-like immunoreactivity apparently identical in the hippocampus and striatum. Furthermore, the control by adenosine A 2A receptors of acetylcholine release from hippocampal nerve terminals obeys the expected pharmacology for adenosine A 2A receptors (antagonism by ZM 241385 and SCH 58261 but not by DPCPX) and requires the activation of the adenylate cyclase/cAMP/protein kinase A pathway, the same biochemical transducing system activated by striatal adenosine A 2A receptors.
The present results are particularly important in light of the several reports showing that the prototypical adenosine A 2A receptor agonist, CGS 21680, essentially binds to extrastriatal regions of the central nervous system to sites apparently different from adenosine A 2A receptors (Cunha et al., 1996 (Cunha et al., , 1999 Johansson and Fredholm, 1995; Johansson et al., 1993; Lindström et al., 1996) . The functional demonstration of pharmacologically well-defined adenosine A 2A receptors in hippocampal neurons extends previous demonstrations that adenosine A 2A receptors mRNA is present in the hippocampus (Cunha et al., 1994a; Dixon et al., 1996; Peterfreund et al., 1996) , namely in neurons (Lopes et al., 2001) , and constitutes a clear demonstration that adenosine A 2A receptors are not confined to the striatum. This had already been proposed in other reports (e.g. Barraco et al., 1995 Barraco et al., , 1996 Li and Henry, 1998; Okada et al., 2001; Phillis, 1998; Robertson and Edwards, 1998) . However, the pharmacological and biochemical data presented in these studies do not allow distinguishing between typical striatal-like adenosine A 2A receptors and atypical receptors and/or binding sites recognized by adenosine A 2A receptor agonists.
It is interesting to note that the cholinergic system appears to display a well-conserved adenosine A 2A receptor-mediated facilitatory system in most preparations where this has been investigated. In fact, the presence of adenosine A 2A receptors has been observed in cholinergic nerve terminals of the striatum (Brown et al., 1990) , in motor nerve terminals (Correia-de-Sá and Ribeiro, 1994) and in Torpedo electric organ nerve terminals (Satoh et al., 1997) , although in the cerebral cortex the picture is less clear (cf. Broad and Fredholm, 1996; Phillis et al., 1993; Spignoli et al., 1984) . As we now observed in the hippocampus, the facilitation of the evoked release of acetylcholine by adenosine A 2A receptors in all these systems is small in amplitude (lower than 30%), appears to be larger in amplitude in intact preparations than in purified nerve terminals (see Cunha et al., 1994a; Jin and Fredholm, 1997) , but always involves the activation of the cAMP/protein kinase A pathway. Interestingly, we had previously reported that the density of adenosine A 2A receptor-like binding sites and the facilitatory effect of CGS 21680 on acetylcholine release were markedly enhanced in the hippocampus of aged rats (Lopes et al., 1999b) . And in these aged animals, but not in young adult rats, we observed that CGS 21680 enhanced the levels of cAMP (Lopes et al., 1999b) , as occurs in the striatum both in young adult and in aged rats. Also, in aged animals, the control of hippocampal glutamatergic transmission is not significantly changed by blockade of adenosine A 1 receptors ) whereas in young adult animals, the adenosine A 2A receptor-mediated facilitation of synaptic transmission is strictly dependent on tonic adenosine A 1 receptor activation (Lopes et al., 2002) . Interestingly, whereas adenosine A 2A receptor facilitation of hippocampal excitatory synaptic inhibition is mediated by protein kinase C in young adult animals (Cunha and Ribeiro, 2000b) , it mostly involves activation of protein kinase A in aged animals ). Thus, it appears that when adenosine A 2A receptor-mediated effects involve protein kinase A, then these effects become independent of adenosine A 1 receptor function, as was presently confirmed for the adenosine A 2A receptor-mediated facilitation of the evoked release of acetylcholine from hippocampal nerve terminals. It should be noted that, although we could not find evidences for the participation of protein kinase C on adenosine A 2A receptor-mediated facilitation of acetylcholine release in hippocampal nerve terminals, we cannot exclude an eventual minor role of this transducing pathway when the protein kinase A pathway is blocked, as was reported to occur in striatal nerve terminals .
The possible physiological role of adenosine A 2A receptors in the control of acetylcholine release in the central nervous system is still ill-defined. In fact, with the experimental conditions used, the predominant effect of adenosine in cholinergic nerve terminals is to activate inhibitory adenosine A 1 receptors (e.g. Jackisch et al., 1984) , as now confirmed by the clear inhibitory effect caused by the closest adenosine analogue, 2-chloroadenosine (see also Cunha et al., 1994a; Jin and Fredholm, 1997) . Only when blocking adenosine A 1 receptors is it possible to reveal an adenosine A 2A receptor-mediated facilitation of acetylcholine release (see also Cunha et al., 1994a; Jin and Fredholm, 1997) . At the motor nerve terminals of the phrenic nerve, the elegant work of the group of Correia-de-Sá et al. (1996) has provided clear evidences that the come into play of adenosine A 2A receptors depends on the frequency of stimulation, but this issue has not yet been tested in cholinergic pathways of the central nervous system.
In conclusion, the present demonstration of the presence of adenosine A 2A receptors in cholinergic nerve terminals of the rat hippocampus clearly shows that adenosine A 2A receptors are not confined to the basal ganglia in the central nervous system.
